{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:42Z","timestamp":1756339422026,"version":"3.44.0"},"reference-count":7,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,11,7]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:p>Posterior reversible encephalopathy syndrome (PRES) is characterised by encephalopathy, visual disturbances and seizures, accompanied by radiological parieto-occipital oedema. Immunosuppressive and immunomodulatory drugs are risk factors. While capecitabine-induced PRES cases are rare, this report details a young woman with advanced gastric adenocarcinoma on capecitabine. She exhibited symptoms of nausea, vomiting and abdominal pain before developing hypertension, drowsiness and a seizure. Brain MRI revealed parieto-occipital hyperintense areas indicative of PRES. Suspending capecitabine led to a gradually improved mental state. Prompt recognition and treatment of PRES offer reversibility, often achievable through dose reduction or discontinuation of the causative drug.<\/jats:p>","DOI":"10.1136\/bcr-2022-252059","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T09:15:33Z","timestamp":1701335733000},"page":"e252059","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Capecitabine-induced posterior reversible encephalopathy syndrome (PRES) in a patient with gastric adenocarcinoma"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8342-9579","authenticated-orcid":false,"given":"Karim","family":"Dirani","sequence":"first","affiliation":[{"name":"DMC, Detroit, Michigan, USA"},{"name":"Ophthalmology, Kresge Eye Institute, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiana","family":"Marusca","sequence":"additional","affiliation":[{"name":"DMC, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"DMC, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Juzych","sequence":"additional","affiliation":[{"name":"DMC, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"2025082702274166000_16.11.e252059.1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12569"},{"key":"2025082702274166000_16.11.e252059.2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/NRL.0000000000000105","article-title":"Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature","volume":"21","author":"How","year":"2016","journal-title":"Neurologist"},{"key":"2025082702274166000_16.11.e252059.3","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1177\/1078155220914704","article-title":"Posterior reversible encephalopathy syndrome: a rare neurotoxicity after capecitabine","volume":"26","author":"Monti","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2025082702274166000_16.11.e252059.4","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.2169\/internalmedicine.0284-17","article-title":"Posterior reversible encephalopathy syndrome after a variety of combined chemotherapies containing bevacizumab for metastatic colon cancer","volume":"57","author":"Katada","year":"2018","journal-title":"Intern Med"},{"key":"2025082702274166000_16.11.e252059.5","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7819-12-264","article-title":"Fatal outcome of posterior 'reversible' encephalopathy syndrome in metastatic colorectal carcinoma after Irinotecan and fluoropyrimidine chemotherapy regimen","volume":"12","author":"Dedi\u0107 Plaveti\u0107","year":"2014","journal-title":"World J Surg Oncol"},{"key":"2025082702274166000_16.11.e252059.6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316225"},{"key":"2025082702274166000_16.11.e252059.7","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1970.00480260061008"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-252059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:27:50Z","timestamp":1756286870000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-252059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":7,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,30]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bcr-2022-252059"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-252059","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}